Cellectricon signs collaboration agreement with AstraZeneca
Cellectricon announced a collaboration with AstraZeneca, under which the companies will study the possibility of developing a new cell-based microfluidic screening platform. The collaboration aims to advance the performance of cell-based ion channel assays in screening applications.
"We are pleased that AstraZeneca sees the value of our microfluidic-based solutions for drug discovery", says Dr. Mattias Karlsson, VP Research & Development at Cellectricon. "The fantastic market acceptance of Dynaflow, our first generation of microfluidic-based tools supports the unique possibilities the micro-scale format offers such as superior performance characteristics and robustness."
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.